Vesynta is a data-guided precision dosing company. They are building clinical decision support software that personalises dose selection, to maximise therapeutic potential. Vesynta’s platform combines drug monitoring data with AI simulations to continuously optimise dose recommendations during clinical trials and by the bedside. The result is safer and more effective treatment, tailored to each patient. Their innovation promises significant advancements in personalized medicine, with applications across various diseases, including cancer. Vesynta’s offerings include SamplePro, a user-friendly mobile app for sample management and data retrieval, and DosoLogic, an AI-driven precision dosing software, housing algorithms powered by pharmacological algorithms that forecasts outcomes for optimised treatment recommendations with remarkable precision.
Status | Active |
Website | https://www.vesynta.com/ |
Category | Digital and AI |
Modality | Digital |
Therapautics Area | Multi-therapeutics |
Headquaters | England, UK |
Investment Portfolio | Fund Investment |